Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McCluskey, Leo
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)	Terminated	3	489	Europe, Canada, US, RoW	Reldesemtiv, Placebo	Cytokinetics	Amyotrophic Lateral Sclerosis	07/23	07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)	Terminated	3	71	Europe, Canada, US, RoW	Reldesemtiv	Cytokinetics, Cytokinetics Inc	Amyotrophic Lateral Sclerosis	06/23	06/23
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS	Recruiting	2/3	230	Canada, US	MN-166, ibudilast, placebo	MediciNova	Amyotrophic Lateral Sclerosis	12/25	12/26
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy	Recruiting	1/2	58	US	NRTX-1001, GABA-secreting interneurons, Sham Comparator	Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)	Mesial Temporal Lobe Epilepsy	02/28	02/42
NCT04559009: COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry	Completed	N/A	47	US		Wake Forest University Health Sciences	Covid19, Amyotrophic Lateral Sclerosis	01/23	01/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McCluskey, Leo
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)	Terminated	3	489	Europe, Canada, US, RoW	Reldesemtiv, Placebo	Cytokinetics	Amyotrophic Lateral Sclerosis	07/23	07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)	Terminated	3	71	Europe, Canada, US, RoW	Reldesemtiv	Cytokinetics, Cytokinetics Inc	Amyotrophic Lateral Sclerosis	06/23	06/23
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS	Recruiting	2/3	230	Canada, US	MN-166, ibudilast, placebo	MediciNova	Amyotrophic Lateral Sclerosis	12/25	12/26
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy	Recruiting	1/2	58	US	NRTX-1001, GABA-secreting interneurons, Sham Comparator	Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)	Mesial Temporal Lobe Epilepsy	02/28	02/42
NCT04559009: COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry	Completed	N/A	47	US		Wake Forest University Health Sciences	Covid19, Amyotrophic Lateral Sclerosis	01/23	01/23